[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Gamblin et al., 2021 - Google Patents

Hemagglutinin structure and activities

Gamblin et al., 2021

View PDF @Free from Publisher
Document ID
7935387057988816060
Author
Gamblin S
Vachieri S
Xiong X
Zhang J
Martin S
Skehel J
Publication year
Publication venue
Cold Spring Harbor Perspectives in Medicine

External Links

Snippet

Hemagglutinins (HAs) are the receptor-binding and membrane fusion glycoproteins of influenza viruses. They recognize sialic acid–containing, cell-surface glycoconjugates as receptors but have limited affinity for them, and, as a consequence, virus attachment to cells …
Continue reading at perspectivesinmedicine.cshlp.org (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Similar Documents

Publication Publication Date Title
Gamblin et al. Hemagglutinin structure and activities
Wu et al. Influenza hemagglutinin structures and antibody recognition
Kosik et al. Influenza hemagglutinin and neuraminidase: Yin–Yang proteins coevolving to thwart immunity
Lamb et al. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface
Xiong et al. Receptor binding properties of the influenza virus hemagglutinin as a determinant of host range
Padilla-Quirarte et al. Protective antibodies against influenza proteins
Cross et al. Mechanisms of cell entry by influenza virus
Stevens et al. Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities
Luo Influenza virus entry
Chutinimitkul et al. Virulence-associated substitution D222G in the hemagglutinin of 2009 pandemic influenza A (H1N1) virus affects receptor binding
Byrd-Leotis et al. Influenza hemagglutinin (HA) stem region mutations that stabilize or destabilize the structure of multiple HA subtypes
Corti et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins
Hong et al. Antibody recognition of the pandemic H1N1 Influenza virus hemagglutinin receptor binding site
CA2790949C (en) Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses
TWI618715B (en) Influenza virus vaccines and uses thereof
Rangel-Moreno et al. B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms
Gambaryan et al. Receptor-binding profiles of H7 subtype influenza viruses in different host species
Krug The influenza viruses
Matsubara et al. Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy
Meischel et al. Influenza A virus interactions with macrophages: lessons from epithelial cells
Crusat et al. Changes in the hemagglutinin of H5N1 viruses during human infection–influence on receptor binding
AU2011210840B2 (en) Engineered polypeptide agents for targeted broad spectrum influenza neutralization
AU2007310753A1 (en) Peptide vaccine for influenza virus
Hillaire et al. Assessment of the antiviral properties of recombinant porcine SP-D against various influenza A viruses in vitro
MX2014003745A (en) Binding molecule having influenza a virus-neutralizing activity produced from human b cell.